Withholding temozolomide based on MGMT methylation is debated because of limitations in methylation assays and lack of alternative therapies.26 We have shown that median survival for patients with unmethylated glioblastoma completing multimodal therapy was 26.1 months. Here, MGMT is linked to glioblastoma.